Harmony Biosciences Holdings (HRMY)
Harmony Biosciences Holdings on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
5.4M
Short interest
settlement 2026-10-15
6.2
Days to cover
+1.2 days vs prior
65.4%
Short share of volume
2026-11-02
940
Fails to deliver
settlement 2026-10-01
Tue 3 Nov
Next earnings
estimated date
-$3.1M
Insider flow, 90 days
0 buys, 7 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in HRMY is 5,413,347 shares, up 784,631 shares over the last month. Over the last 48 readings it ranged from 2,551,889 shares (15 May 2025) to 7,948,986 shares (27 February 2026). At the reported average volume of 876K shares a day that is 6.2 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/hrmy" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 5,413,347 | -2.1% | 876,105 | 6.18 |
| 2026-09-30 | 5,532,301 | +19.5% | 1,108,114 | 4.99 |
| 2026-09-15 | 4,628,716 | -10.4% | 1,067,713 | 4.34 |
| 2026-08-31 | 5,164,996 | +24.9% | 566,650 | 9.11 |
| 2026-08-14 | 4,136,259 | -8.0% | 866,805 | 4.77 |
| 2026-07-31 | 4,496,943 | -12.1% | 889,701 | 5.05 |
| 2026-07-15 | 5,114,969 | +10.9% | 754,093 | 6.78 |
| 2026-06-30 | 4,611,754 | -0.7% | 809,566 | 5.70 |
| 2026-06-15 | 4,645,233 | -21.8% | 894,751 | 5.19 |
| 2026-05-29 | 5,940,252 | -10.2% | 689,110 | 8.62 |
| 2026-05-15 | 6,618,020 | -4.1% | 805,911 | 8.21 |
| 2026-04-30 | 6,901,998 | -5.3% | 1,077,880 | 6.40 |
| 2026-04-15 | 7,290,999 | -4.7% | 610,500 | 11.94 |
| 2026-03-31 | 7,647,217 | +0.3% | 729,344 | 10.49 |
| 2026-03-13 | 7,622,382 | -4.1% | 708,852 | 10.75 |
| 2026-02-27 | 7,948,986 | +47.0% | 1,829,054 | 4.35 |
| 2026-02-13 | 5,407,171 | -4.7% | 518,683 | 10.42 |
| 2026-01-30 | 5,675,393 | -5.3% | 547,333 | 10.37 |
| 2026-01-15 | 5,990,113 | +37.6% | 734,692 | 8.15 |
| 2025-12-31 | 4,354,263 | +0.3% | 550,068 | 7.92 |
| 2025-12-15 | 4,342,807 | -1.6% | 788,499 | 5.51 |
| 2025-11-28 | 4,412,922 | +3.0% | 827,410 | 5.33 |
| 2025-11-14 | 4,285,274 | +5.0% | 1,029,047 | 4.16 |
| 2025-10-31 | 4,082,621 | +9.5% | 806,405 | 5.06 |
| 2025-10-15 | 3,728,984 | +15.6% | 880,466 | 4.24 |
| 2025-09-30 | 3,226,662 | -24.0% | 1,164,736 | 2.77 |
| 2025-09-15 | 4,247,460 | -2.0% | 915,370 | 4.64 |
| 2025-08-29 | 4,334,580 | +1.5% | 441,628 | 9.82 |
| 2025-08-15 | 4,271,705 | +1.1% | 581,958 | 7.34 |
| 2025-07-31 | 4,224,989 | -5.0% | 612,928 | 6.89 |
| 2025-07-15 | 4,447,290 | +0.7% | 541,799 | 8.21 |
| 2025-06-30 | 4,415,410 | +19.1% | 664,020 | 6.65 |
| 2025-06-13 | 3,706,527 | +9.7% | 633,818 | 5.85 |
| 2025-05-30 | 3,378,904 | +32.4% | 634,516 | 5.33 |
| 2025-05-15 | 2,551,889 | -21.5% | 844,269 | 3.02 |
| 2025-04-30 | 3,249,487 | -0.0% | 556,318 | 5.84 |
| 2025-04-15 | 3,250,684 | -6.9% | 813,917 | 3.99 |
| 2025-03-31 | 3,493,041 | -15.1% | 763,749 | 4.57 |
| 2025-03-14 | 4,114,521 | +5.6% | 583,121 | 7.06 |
| 2025-02-28 | 3,896,324 | +3.9% | 943,827 | 4.13 |
| 2025-02-14 | 3,748,832 | -0.5% | 516,078 | 7.26 |
| 2025-01-31 | 3,766,549 | -31.8% | 632,817 | 5.95 |
| 2025-01-15 | 5,525,088 | -3.2% | 452,391 | 12.21 |
| 2024-12-31 | 5,705,195 | +4.8% | 638,065 | 8.94 |
| 2024-12-13 | 5,443,204 | -0.0% | 475,726 | 11.44 |
| 2024-11-29 | 5,445,550 | -6.1% | 384,129 | 14.18 |
| 2024-11-15 | 5,798,106 | -4.3% | 1,139,526 | 5.09 |
| 2024-10-31 | 6,056,425 | -18.7% | 1,131,125 | 5.35 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of HRMY volume is 65.4%, down 12.6 points over the last five sessions. Over the last 30 readings it ranged from 56.2% (25 September 2026) to 90.1% (22 October 2026). The latest reading is 8.8 points below the 30-session average of 74.2%, on 348K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 228K | 348K | 65.4% | 0 |
| 2026-10-30 | 183K | 312K | 58.7% | 112 |
| 2026-10-29 | 235K | 325K | 72.5% | 0 |
| 2026-10-28 | 284K | 395K | 71.9% | 0 |
| 2026-10-27 | 199K | 252K | 78.9% | 0 |
| 2026-10-26 | 247K | 317K | 78.0% | 0 |
| 2026-10-23 | 734K | 818K | 89.7% | 3,440 |
| 2026-10-22 | 1.2M | 1.3M | 90.1% | 50 |
| 2026-10-21 | 327K | 526K | 62.2% | 0 |
| 2026-10-20 | 315K | 374K | 84.2% | 0 |
| 2026-10-19 | 328K | 396K | 82.9% | 65 |
| 2026-10-16 | 355K | 429K | 82.8% | 0 |
| 2026-10-15 | 161K | 246K | 65.3% | 0 |
| 2026-10-14 | 239K | 348K | 68.8% | 0 |
| 2026-10-13 | 484K | 615K | 78.7% | 0 |
| 2026-10-12 | 388K | 458K | 84.7% | 200 |
| 2026-10-09 | 141K | 185K | 75.9% | 0 |
| 2026-10-08 | 166K | 214K | 77.9% | 0 |
| 2026-10-07 | 189K | 231K | 81.8% | 0 |
| 2026-10-06 | 146K | 188K | 77.7% | 0 |
| 2026-10-05 | 196K | 251K | 77.9% | 0 |
| 2026-10-02 | 215K | 291K | 73.8% | 0 |
| 2026-10-01 | 308K | 447K | 68.9% | 0 |
| 2026-09-30 | 136K | 219K | 61.9% | 149 |
| 2026-09-29 | 282K | 370K | 76.3% | 0 |
| 2026-09-28 | 242K | 350K | 69.2% | 3,955 |
| 2026-09-25 | 123K | 219K | 56.2% | 0 |
| 2026-09-24 | 326K | 452K | 72.0% | 0 |
| 2026-09-23 | 313K | 417K | 75.2% | 1,398 |
| 2026-09-22 | 119K | 179K | 66.4% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 1 October 2026, the fails-to-deliver balance in HRMY is 940 shares, down 2,165 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (1 June 2026) to 85,000 shares (20 May 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-01 | 940 | $39.26 | $37K |
| 2026-09-25 | 3,105 | $41.16 | $128K |
| 2026-09-21 | 60 | $42.02 | $3K |
| 2026-09-15 | 3,728 | $41.54 | $155K |
| 2026-09-09 | 47,140 | $42.07 | $2.0M |
| 2026-09-03 | 30,438 | $42.86 | $1.3M |
| 2026-09-01 | 166 | $39.38 | $7K |
| 2026-08-24 | 295 | $38.15 | $11K |
| 2026-08-10 | 16,419 | $38.41 | $631K |
| 2026-07-20 | 2,000 | $33.77 | $68K |
| 2026-07-17 | 90 | $33.53 | $3K |
| 2026-07-14 | 30,000 | $35.54 | $1.1M |
| 2026-07-08 | 33 | $38.26 | $1K |
| 2026-06-25 | 72,587 | $34.45 | $2.5M |
| 2026-06-24 | 3 | $34.16 | $102 |
| 2026-06-15 | 28 | $34.46 | $965 |
| 2026-06-12 | 27,770 | $35.20 | $978K |
| 2026-06-11 | 38,780 | $35.48 | $1.4M |
| 2026-06-10 | 266 | $34.10 | $9K |
| 2026-06-04 | 415 | $32.10 | $13K |
| 2026-06-03 | 170 | $30.91 | $5K |
| 2026-06-01 | 2 | $31.59 | $63 |
| 2026-05-20 | 85,000 | $30.44 | $2.6M |
| 2026-05-05 | 83 | $32.59 | $3K |
| 2026-04-27 | 107 | $30.80 | $3K |
| 2026-04-22 | 5 | $32.14 | $161 |
| 2026-04-20 | 17 | $29.99 | $510 |
| 2026-03-25 | 240 | $27.10 | $7K |
| 2026-03-23 | 20 | $27.72 | $554 |
| 2026-02-26 | 3,987 | $28.19 | $112K |
Insider trades
SEC Form 4, newest first. JSONInsiders at HRMY reported 7 open-market sells worth $3.1M in the last 90 days and no open-market buys. Latest filing: Budur Kumar (CHIEF MEDICAL OFFICER) on 2026-09-18.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-18 | Budur Kumar | CHIEF MEDICAL OFFICER | Sell | 36K | $43.05 | $1.5M | 13K |
| 2026-09-18 | Budur Kumar | CHIEF MEDICAL OFFICER | Exercise or conversion | 25K | $30.27 | $770K | 49K |
| 2026-09-18 | Budur Kumar | CHIEF MEDICAL OFFICER | Exercise or conversion | 10K | $30.69 | $319K | 24K |
| 2026-09-17 | Budur Kumar | CHIEF MEDICAL OFFICER | Exercise or conversion | 400 | $30.27 | $12K | 14K |
| 2026-09-17 | Budur Kumar | CHIEF MEDICAL OFFICER | Sell | 800 | $43.00 | $34K | 13K |
| 2026-09-17 | Budur Kumar | CHIEF MEDICAL OFFICER | Exercise or conversion | 400 | $30.69 | $12K | 14K |
| 2026-09-16 | Budur Kumar | CHIEF MEDICAL OFFICER | Exercise or conversion | 900 | $30.27 | $27K | 15K |
| 2026-09-16 | Budur Kumar | CHIEF MEDICAL OFFICER | Sell | 2K | $43.01 | $77K | 13K |
| 2026-09-16 | Budur Kumar | CHIEF MEDICAL OFFICER | Exercise or conversion | 900 | $30.69 | $28K | 14K |
| 2026-09-08 | Budur Kumar | CHIEF MEDICAL OFFICER | Sell | 23K | $43.10 | $989K | 13K |
| 2026-09-08 | Budur Kumar | CHIEF MEDICAL OFFICER | Exercise or conversion | 11K | $30.27 | $326K | 36K |
| 2026-09-08 | Budur Kumar | CHIEF MEDICAL OFFICER | Exercise or conversion | 12K | $30.69 | $374K | 25K |
| 2026-09-08 | Budur Kumar | CHIEF MEDICAL OFFICER | Sell | 1K | $42.79 | $43K | 13K |
| 2026-09-08 | Budur Kumar | CHIEF MEDICAL OFFICER | Sell | 5K | $42.25 | $190K | 14K |
| 2026-09-04 | Budur Kumar | CHIEF MEDICAL OFFICER | Sell | 6K | $41.98 | $231K | 19K |
| 2026-05-01 | Budur Kumar | CHIEF MEDICAL OFFICER | Tax withholding | 9K | $31.83 | $283K | 24K |
| 2026-05-01 | Budur Kumar | CHIEF MEDICAL OFFICER | Exercise or conversion | 19K | $0.00 | $0 | 33K |
| 2026-04-07 | Zaeske Adam H. | CHIEF COMMERCIAL OFFICER | Tax withholding | 3K | $27.62 | $88K | 4K |
| 2026-04-07 | Zaeske Adam H. | CHIEF COMMERCIAL OFFICER | Exercise or conversion | 8K | $0.00 | $0 | 8K |
| 2026-01-26 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 4K | $37.15 | $139K | 25K |
| 2026-01-25 | Serafin Andrew | CHIEF STRATEGY OFFICER | Tax withholding | 1K | $36.82 | $41K | 1K |
| 2026-01-25 | Serafin Andrew | CHIEF STRATEGY OFFICER | Exercise or conversion | 3K | $0.00 | $0 | 3K |
| 2026-01-25 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Tax withholding | 3K | $36.82 | $94K | 2K |
| 2026-01-25 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Exercise or conversion | 5K | $0.00 | $0 | 5K |
| 2026-01-25 | Dayno Jeffrey M. | PRESIDENT, CEO | Tax withholding | 6K | $36.82 | $208K | 7K |
| 2026-01-25 | Dayno Jeffrey M. | PRESIDENT, CEO | Exercise or conversion | 13K | $0.00 | $0 | 13K |
| 2026-01-25 | Budur Kumar | CHIEF MEDICAL OFFICER | Tax withholding | 1K | $36.82 | $51K | 1K |
| 2026-01-25 | Budur Kumar | CHIEF MEDICAL OFFICER | Exercise or conversion | 3K | $0.00 | $0 | 3K |
| 2026-01-24 | Serafin Andrew | CHIEF STRATEGY OFFICER | Tax withholding | 1K | $36.82 | $41K | 1K |
| 2026-01-24 | Serafin Andrew | CHIEF STRATEGY OFFICER | Exercise or conversion | 3K | $0.00 | $0 | 3K |
| 2026-01-24 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Tax withholding | 2K | $36.82 | $82K | 2K |
| 2026-01-24 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Exercise or conversion | 4K | $0.00 | $0 | 4K |
| 2026-01-24 | Dayno Jeffrey M. | PRESIDENT, CEO | Tax withholding | 5K | $36.82 | $176K | 6K |
| 2026-01-24 | Dayno Jeffrey M. | PRESIDENT, CEO | Exercise or conversion | 11K | $0.00 | $0 | 11K |
| 2026-01-24 | Budur Kumar | CHIEF MEDICAL OFFICER | Tax withholding | 1K | $36.82 | $42K | 1K |
| 2026-01-24 | Budur Kumar | CHIEF MEDICAL OFFICER | Exercise or conversion | 2K | $0.00 | $0 | 2K |
| 2026-01-15 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 21K | $35.92 | $753K | 0 |
| 2025-12-12 | Dayno Jeffrey M. | PRESIDENT, CEO | Sell | 6K | $40.11 | $238K | 0 |
| 2025-12-12 | Dayno Jeffrey M. | PRESIDENT, CEO | Sell | 20K | $40.11 | $802K | 0 |
| 2025-12-12 | Dayno Jeffrey M. | PRESIDENT, CEO | Exercise or conversion | 20K | $8.22 | $164K | 20K |
| 2025-12-05 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 20K | $39.54 | $791K | 0 |
| 2025-12-05 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Exercise or conversion | 20K | $29.03 | $581K | 20K |
| 2025-11-21 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 3K | $35.00 | $120K | 0 |
| 2025-09-30 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Tax withholding | 24K | $27.56 | $663K | 21K |
| 2025-09-30 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Exercise or conversion | 45K | $0.00 | $0 | 45K |
| 2025-08-28 | Sabater Juan A. | Director,TenPercentOwner | Other transaction | 6.6M | price not stated in the filing | not stated | 0 |
| 2025-08-15 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 22K | $36.50 | $787K | 0 |
| 2025-05-01 | Budur Kumar | CHIEF MEDICAL OFFICER | Exercise or conversion | 19K | $0.00 | $0 | 19K |
| 2025-05-01 | Budur Kumar | CHIEF MEDICAL OFFICER | Tax withholding | 9K | $29.86 | $265K | 10K |
| 2025-04-01 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 740 | $33.12 | $25K | 0 |
| 2025-04-01 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 6K | $32.48 | $203K | 740 |
| 2025-03-29 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Exercise or conversion | 15K | $0.00 | $0 | 15K |
| 2025-03-29 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Tax withholding | 8K | $33.19 | $266K | 7K |
| 2025-03-03 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 4K | $32.61 | $142K | 500 |
| 2025-03-03 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 500 | $33.23 | $17K | 0 |
| 2025-03-03 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Exercise or conversion | 5K | $8.22 | $40K | 5K |
| 2025-01-27 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 2K | $38.05 | $68K | 0 |
| 2025-01-27 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 2K | $38.02 | $62K | 0 |
| 2025-01-24 | Serafin Andrew | CHIEF STRATEGY OFFICER | Tax withholding | 865 | $38.01 | $33K | 2K |
| 2025-01-24 | Serafin Andrew | CHIEF STRATEGY OFFICER | Exercise or conversion | 3K | $0.00 | $0 | 3K |
| 2025-01-24 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Exercise or conversion | 4K | $0.00 | $0 | 4K |
| 2025-01-24 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Tax withholding | 2K | $38.01 | $77K | 2K |
| 2025-01-24 | Dayno Jeffrey M. | PRESIDENT, CEO | Exercise or conversion | 11K | $0.00 | $0 | 11K |
| 2025-01-24 | Dayno Jeffrey M. | PRESIDENT, CEO | Tax withholding | 5K | $38.01 | $174K | 6K |
| 2025-01-24 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 5K | $37.87 | $194K | 0 |
| 2025-01-24 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Tax withholding | 1K | $38.01 | $40K | 2K |
| 2025-01-24 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Exercise or conversion | 3K | $0.00 | $0 | 3K |
| 2025-01-24 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 8K | $36.94 | $296K | 5K |
| 2025-01-24 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Exercise or conversion | 13K | $30.69 | $403K | 13K |
| 2025-01-24 | Budur Kumar | CHIEF MEDICAL OFFICER | Tax withholding | 1K | $38.01 | $44K | 1K |
| 2025-01-24 | Budur Kumar | CHIEF MEDICAL OFFICER | Exercise or conversion | 2K | $0.00 | $0 | 2K |
| 2025-01-21 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 1K | $40.00 | $45K | 0 |
| 2025-01-21 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Exercise or conversion | 1K | $33.44 | $38K | 1K |
| 2025-01-21 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Sell | 25K | $40.18 | $1.0M | 0 |
| 2025-01-21 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Exercise or conversion | 25K | $29.03 | $726K | 25K |
| 2025-01-21 | Dayno Jeffrey M. | PRESIDENT, CEO | Sell | 19K | $40.13 | $774K | 0 |
| 2025-01-21 | Dayno Jeffrey M. | PRESIDENT, CEO | Exercise or conversion | 19K | $8.22 | $159K | 19K |
| 2025-01-16 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 29K | $37.41 | $1.1M | 0 |
| 2025-01-16 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Exercise or conversion | 29K | $33.44 | $986K | 29K |
| 2025-01-15 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Exercise or conversion | 11K | $33.44 | $351K | 11K |
| 2025-01-15 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 11K | $37.01 | $389K | 0 |
| 2025-01-13 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Exercise or conversion | 7K | $33.44 | $240K | 7K |
| 2025-01-13 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 7K | $37.04 | $266K | 0 |
| 2024-11-05 | Marshman Fund Trust II | TenPercentOwner | Sell | 600K | $30.30 | $18.2M | 6.1M |
| 2024-11-05 | VALOR EQUITY PARTNERS IV-B L.P. | TenPercentOwner | Sell | 600K | $30.30 | $18.2M | 6.6M |
| 2024-11-01 | Marshman Fund Trust II | TenPercentOwner | Sell | 4.0M | $30.30 | $121.2M | 6.7M |
| 2024-11-01 | VALOR EQUITY PARTNERS IV-B L.P. | TenPercentOwner | Sell | 4.0M | $30.30 | $121.2M | 7.2M |
| 2024-10-29 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 21K | $40.47 | $870K | 0 |
| 2024-10-29 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Exercise or conversion | 21K | $24.00 | $516K | 21K |
| 2024-10-03 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 705 | $35.62 | $25K | 0 |
| 2024-10-03 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 36K | $35.05 | $1.2M | 705 |
| 2024-10-01 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 400 | $40.19 | $16K | 0 |
| 2024-10-01 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Exercise or conversion | 400 | $24.00 | $10K | 400 |
| 2024-09-30 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 36K | $40.03 | $1.4M | 0 |
| 2024-09-30 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Exercise or conversion | 36K | $24.00 | $860K | 36K |
| 2024-09-30 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Exercise or conversion | 60K | $0.00 | $0 | 60K |
| 2024-09-30 | Kapadia Sandip | CHIEF FINANCIAL OFFICER | Tax withholding | 32K | $40.00 | $1.3M | 28K |
| 2024-09-30 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Tax withholding | 24K | $40.00 | $946K | 36K |
| 2024-09-30 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Exercise or conversion | 60K | $0.00 | $0 | 60K |
| 2024-09-27 | Dierks Jeffrey | CHIEF COMMERCIAL OFFICER | Sell | 200 | $40.05 | $8K | 0 |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON19 Form 144 notices on file for HRMY worth $39.6M at the prices reported; 6 in the last 90 days worth $29.6M. Latest: KUMAR BUDUR filed on 2026-09-18 to sell 35,852 shares ($1.5M) from 2026-09-18.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-18 | KUMAR BUDUROfficer | 36K | $1.5M | 0.062% | 2026-09-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-17 | KUMAR BUDUROfficer | 800 | $34K | 0.001% | 2026-09-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-16 | KUMAR BUDUROfficer | 2K | $76K | 0.003% | 2026-09-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-08 | KUMAR BUDUROfficer | 28K | $1.2M | 0.049% | 2026-09-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-04 | KUMAR BUDUROfficer | 6K | $230K | 0.009% | 2026-09-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-07 | VALOR IV PHARMA HOLDINGS LLCDirector | 701K | $26.6M | 1.204% | 2026-08-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-02 | SANDIP KAPADIAFormer Officer | 25K | $924K | 0.043% | 2026-07-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-30 | SANDIP KAPADIAFormer Officer | 50K | $1.8M | 0.086% | 2026-06-30 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-26 | SANDIP KAPADIAFormer Officer | 46K | $1.6M | 0.079% | 2026-06-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-24 | SANDIP KAPADIAFormer Officer | 4K | $154K | 0.008% | 2026-06-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-09 | SANDIP KAPADIAFormer Officer | 28K | $943K | 0.048% | 2026-06-09 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-05 | SANDIP KAPADIAFormer Officer | 2K | $70K | 0.004% | 2026-06-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-04 | SANDIP KAPADIAFormer Officer | 7K | $233K | 0.012% | 2026-06-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-08 | SANDIP KAPADIAFormer Officer | 45K | $1.4M | 0.079% | 2026-05-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-26 | SANDIP KAPADIAOfficer | 4K | $138K | 0.007% | 2026-01-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-15 | SANDIP KAPADIAOfficer | 21K | $755K | 0.036% | 2026-01-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-12 | JEFFREY M DAYNODirector, Officer | 26K | $1.0M | 0.045% | 2025-12-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-05 | SANDIP KAPADIAOfficer | 20K | $765K | 0.035% | 2025-12-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-21 | SANDIP KAPADIAOfficer | 3K | $114K | 0.006% | 2025-11-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON4 holders report 5% or more of HRMY in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 12.6% of the class (7,361,888 shares), filed 2026-10-27 for an event on 2026-09-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-27 | 13G/Ano. 7 | BlackRock, Inc.parent holding company | 7.4M | 12.6% | 2026-09-30 |
| 2026-07-31 | 13G | Vanguard Portfolio Managementinvestment adviser | 2.9M | 5.1% | 2026-06-30 |
| 2026-03-27 | 13G/Ano. 3 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-05 | 13G/Ano. 7 | FMR LLCparent holding company | 3.1M | 5.4% | 2025-12-31 |
| 2026-02-05 | 13G/Ano. 7 | Abigail P. Johnsonindividual | 3.1M | 5.4% | 2025-12-31 |
| 2025-11-14 | 13G/Ano. 5 | Antonio J. Graciasindividual | 1.8M | 3.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 5 | Juan A. Sabaterindividual | 1.4M | 2.4% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 5 | Valor Equity Associates IV L.P.parent holding company | 1.3M | 2.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 5 | Valor Equity Capital IV LLCparent holding company | 1.3M | 2.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 5 | Valor Management L.P.parent holding company | 1.3M | 2.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 5 | Valor Equity Partners IV L.P.partnership | 767K | 1.3% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 5 | Valor Equity Partners IV-B L.P.partnership | 397K | 0.7% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 5 | Valor Equity Partners IV-A L.P.partnership | 0 | 0.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 5 | Valor IV Pharma Holdings, LLCother entity | 0 | 0.0% | 2025-09-30 |
13F holders
Tracked managers holding HRMY at their latest 13F. JSON7 of the 30 tracked managers held HRMY at their latest 13F, $144.4M in total at quarter-end prices. Renaissance Technologies is the largest at $43.5M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 1.2M | $43.5M | 0.06% | +118K |
| Two Sigma Investments | 2026-06-30 | 959K | $34.9M | 0.03% | +226K |
| AQR Capital Management | 2026-06-30 | 934K | $34.0M | 0.01% | +218K |
| Millennium Management | 2026-06-30 | 320K | $11.6M | 0.00% | -635K |
| Citadel Advisors | 2026-06-30 | 256K | $9.3M | 0.00% | -330K |
| Bridgewater Associates | 2026-06-30 | 249K | $9.1M | 0.04% | -3K |
| D. E. Shaw & Co. | 2026-06-30 | 53K | $1.9M | 0.00% | -49K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Harmony Biosciences Holdings reported revenue of $261.3M, up 30.3% from the same quarter a year earlier, and net income of $75.4M (1.28 diluted EPS). In FY 2025 it generated $348.2M of operating cash flow. As of 2026-06-30, cash was $549.8M against $154.0M of debt.
- Cash
- $549.8M
- Debt
- $154.0M
- Equity
- $999.2M
- Total assets
- $1.37B
- Shares outstanding
- 58,236,393
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $261.3M | $75.4M | 28.9% | 1.28 |
| Q1 FY 2026 | 2026-03-31 | $215.4M | $32.5M | 15.1% | 0.55 |
| Q4 FY 2025derived | 2025-12-31 | $243.8M | $22.5M | 9.2% | n/a |
| Q3 FY 2025 | 2025-09-30 | $239.5M | $50.9M | 21.2% | 0.87 |
| Q2 FY 2025 | 2025-06-30 | $200.5M | $39.8M | 19.8% | 0.68 |
| Q1 FY 2025 | 2025-03-31 | $184.7M | $45.6M | 24.7% | 0.78 |
| Q4 FY 2024derived | 2024-12-31 | $201.3M | $49.5M | 24.6% | n/a |
| Q3 FY 2024 | 2024-09-30 | $186.0M | $46.1M | 24.8% | 0.79 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $868.5M | $158.7M | $348.2M | $310K | n/a | n/a |
| FY 2024 | 2024-12-31 | $714.7M | $145.5M | $219.8M | $1.2M | n/a | n/a |
| FY 2023 | 2023-12-31 | $582.0M | $128.9M | $219.4M | $312K | $100.0M | n/a |
| FY 2022 | 2022-12-31 | $437.9M | $181.5M | $144.5M | $172K | n/a | n/a |
| FY 2021 | 2021-12-31 | $305.4M | $34.6M | $98.6M | $298K | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.
What this page is
Harmony Biosciences Holdings in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Harmony Biosciences Holdings (HRMY), SEC CIK 1802665, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-01.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-18.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-27.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-04.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-18.JSON and CSV
- Company record
- EDGAR filing index for CIK 1802665Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of HRMY is sold short?
5,413,347 shares were held short at the 2026-10-15 settlement, 6.2 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is HRMY's daily short volume?
On 2026-11-02, 227,724 of the 348,284 HRMY shares reported to FINRA were sold short, 65.4% of the day's reported volume. Short volume is a flow for one day, not a position.
Does HRMY have fails to deliver?
The SEC's latest file shows 940 HRMY shares failed to deliver at settlement 2026-10-01. Fails are reported per settlement date and published twice a month with a lag.
Are HRMY insiders buying or selling?
Insiders at HRMY reported 7 open-market sells worth $3.1M in the last 90 days and no open-market buys. Latest filing: Budur Kumar (CHIEF MEDICAL OFFICER) on 2026-09-18.
Have HRMY insiders filed to sell?
19 Form 144 notices on file for HRMY worth $39.6M at the prices reported; 6 in the last 90 days worth $29.6M. Latest: KUMAR BUDUR filed on 2026-09-18 to sell 35,852 shares ($1.5M) from 2026-09-18.
Who owns 5% or more of HRMY?
4 holders report 5% or more of HRMY in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 12.6% of the class (7,361,888 shares), filed 2026-10-27 for an event on 2026-09-30.
What did HRMY report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Harmony Biosciences Holdings reported revenue of $261.3M, up 30.3% from the same quarter a year earlier, and net income of $75.4M (1.28 diluted EPS). In FY 2025 it generated $348.2M of operating cash flow. As of 2026-06-30, cash was $549.8M against $154.0M of debt.
Which tracked 13F managers own HRMY?
7 of the 30 tracked 13F managers held HRMY shares at their latest filing, $144.4M in all. The largest: Renaissance Technologies (1.2M shares, $43.5M), Two Sigma Investments (959K shares, $34.9M), Cliff Asness's AQR Capital Management (934K shares, $34.0M), Izzy Englander's Millennium Management (320K shares, $11.6M), Ken Griffin's Citadel Advisors (256K shares, $9.3M), Ray Dalio's Bridgewater Associates (249K shares, $9.1M). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.